FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.
What happened
FDA reviewed the website www.derma-solution.com and found it offered injectable botulinum toxin type A products marketed as “Botulax 300 Units” and “Botulax 300.” FDA said these are unapproved new drugs without an FDA-approved application and that their labeling lacks adequate directions for use. FDA did not conduct an inspection; this was a website review.
What FDA found
The website offers Botulax botulinum toxin drugs without an FDA-approved application, so they are unapproved new drugs.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]Botulax is a new drug because it is not generally recognized as safe and effective for its labeled uses.
FD&C Act § 201(p) [21 U.S.C. § 321(p)]The drug labeling does not give adequate directions for safe use by a layperson.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The drugs are not exempt from adequate-directions labeling because they are not approved in the U.S.
21 CFR 201.115(a)Offering these drugs for sale causes misbranded drugs to enter interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]The products are prescription drugs that cannot be used safely without a licensed practitioner’s supervision.
FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]
What FDA wants
FDA asks Derma Solution to stop offering unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with the specific corrective steps taken and related documentation.
Who should pay attention
- online sellers of aesthetic or prescription injectables
- clinics and med spas buying botulinum toxin products
- businesses or consumers sourcing unapproved Botox alternatives online
This is a summary. Read the original letter on fda.gov.